These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 24128806)

  • 1. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.
    Soldà F; Lodge M; Ashley S; Whitington A; Goldstraw P; Brada M
    Radiother Oncol; 2013 Oct; 109(1):1-7. PubMed ID: 24128806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study.
    de Ruiter JC; van der Noort V; van Diessen JNA; Smit EF; Damhuis RAM; Hartemink KJ;
    Lung Cancer; 2024 May; 191():107792. PubMed ID: 38621343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.
    Chang JY; Mehran RJ; Feng L; Verma V; Liao Z; Welsh JW; Lin SH; O'Reilly MS; Jeter MD; Balter PA; McRae SE; Berry D; Heymach JV; Roth JA;
    Lancet Oncol; 2021 Oct; 22(10):1448-1457. PubMed ID: 34529930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer?
    Mahmood S; Bilal H; Faivre-Finn C; Shah R
    Interact Cardiovasc Thorac Surg; 2013 Nov; 17(5):845-53. PubMed ID: 23900381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
    Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
    Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
    Phillips I; Sandhu S; Lüchtenborg M; Harden S
    Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC.
    van den Berg LL; Klinkenberg TJ; Groen HJM; Widder J
    J Thorac Oncol; 2015 May; 10(5):826-831. PubMed ID: 25629639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer.
    Lagerwaard FJ; Verstegen NE; Haasbeek CJ; Slotman BJ; Paul MA; Smit EF; Senan S
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):348-53. PubMed ID: 22104360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic ablative body radiotherapy (SABR): an alternative to surgery in stage I-II non-small-cell cancer of the lung?
    Mirimanoff RO
    Chin Clin Oncol; 2015 Dec; 4(4):42. PubMed ID: 26730754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review.
    Senthi S; Haasbeek CJ; Slotman BJ; Senan S
    Radiother Oncol; 2013 Mar; 106(3):276-82. PubMed ID: 23462705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Ablative Radiation Therapy for the Treatment of Early-stage Non-Small-Cell Lung Cancer: CEPO Review and Recommendations.
    Boily G; Filion É; Rakovich G; Kopek N; Tremblay L; Samson B; Goulet S; Roy I;
    J Thorac Oncol; 2015 Jun; 10(6):872-82. PubMed ID: 26001140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
    Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
    Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis.
    Mokhles S; Verstegen N; Maat AP; Birim Ö; Bogers AJ; Mokhles MM; Lagerwaard FJ; Senan S; Takkenberg JJ
    Lung Cancer; 2015 Mar; 87(3):283-9. PubMed ID: 25622781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
    Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
    Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer.
    Brooks ED; Sun B; Feng L; Verma V; Zhao L; Gomez DR; Liao Z; Jeter M; O'Reilly M; Welsh JW; Nguyen QN; Erasmus JJ; Eapen G; Ahrar K; Antonoff MB; Hahn SM; Heymach JV; Rice DC; Chang JY
    JAMA Netw Open; 2018 Aug; 1(4):e181390. PubMed ID: 30646121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.
    Ricardi U; Frezza G; Filippi AR; Badellino S; Levis M; Navarria P; Salvi F; Marcenaro M; Trovò M; Guarneri A; Corvò R; Scorsetti M
    Lung Cancer; 2014 Jun; 84(3):248-53. PubMed ID: 24681279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is radiofrequency ablation more effective than stereotactic ablative radiotherapy in patients with early stage medically inoperable non-small cell lung cancer?
    Bilal H; Mahmood S; Rajashanker B; Shah R
    Interact Cardiovasc Thorac Surg; 2012 Aug; 15(2):258-65. PubMed ID: 22581864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.